Preclinical study indicates that morpholino-mediated FOXP3 isoform shifting is a potentially promising immunotherapeutic approach for cancer treatment.

Midkine, one of the most correlated proteins with amyloid beta in Alzheimer's brains, is now shown to attenuate amyloid plaques.